TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07895992: A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 in Combination With Bevacizumab Versus Sacituzumab Tirumotecan in Advanced or Metastatic Non-small Cell Lung Cancer

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 490 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07895992 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07895992 Rescue Dossier →